Conclusion: Humana’s improved 2027 Medicare Advantage Star Ratings are a meaningful positive for its long-term earnings outlook, but they are not immediate revenue or guaranteed profit. The company said 95% of its Medicare Advantage members are now in contracts rated four stars or higher, restoring eligibility for future quality bonuses. Investors should still watch medical costs, enrollment and spending plans before treating the rebound as a complete turnaround.
What happened
On October 9, 2026, Humana announced that 95% of its Medicare Advantage members were enrolled in contracts rated four stars or above in the federal government’s final 2027 ratings. The company reported six contracts rated 4.5 stars and 12 rated 4.0 stars, 11 more highly rated contracts than a year earlier. Humana’s prescription-drug-plan contract also earned 4.5 stars.
How Medicare Star Ratings work
The Centers for Medicare & Medicaid Services, or CMS, scores Medicare Advantage and drug plans from one to five stars. The ratings summarize preventive care, chronic-condition management, customer service and member experience. Consumers use them to compare plans, while contracts with at least four stars can qualify for federal quality bonuses.
CMS released the underlying 2027 ratings on October 8. Humana’s announcement and the major stock reaction followed on October 9. CMS said about 71% of people enrolled in Medicare Advantage plans with drug coverage are currently in contracts rated four stars or higher; 37% of contracts offered for 2027 reached that threshold. The figures were checked against the CMS fact sheet, Humana announcement and Reuters report.
Why the ratings improved
Humana attributed the result to operational changes, data and analytics, and an “always-on” approach to quality improvement. The company had suffered a sharp ratings decline two years earlier, so restoring four-star status for key contracts was central to its recovery plan. A four-star rating matters financially because it can unlock bonus payments and provide more resources for benefits or lower premiums.
The timing is important
The ratings are labeled 2027 because shoppers will see them during the 2027 Medicare open-enrollment period, from October 15 through December 7, 2026. CMS says they will affect 2028 quality-bonus payments. That delay matters: the ratings improve future visibility, but do not instantly add cash to Humana’s current-quarter results.
What it means for personal money and investing
Members and shareholders see different effects
For Medicare shoppers, a higher rating is useful evidence of plan quality, but it should not replace a comparison of premiums, drug coverage, provider networks and out-of-pocket limits. A highly rated plan may still be a poor fit for a person’s doctors or prescriptions.
For HUM shareholders, broader bonus eligibility can support margins and competitiveness. The shares jumped about 14% in premarket trading after the data became clear, showing that investors had assigned substantial uncertainty to the outcome. However, a one-day move is not proof of lasting earnings growth. Healthcare utilization, reimbursement policy, member retention and benefit costs can offset part of the advantage.
What to watch next
Watch enrollment during the October 15–December 7 selection period, Humana’s 2028 earnings framework and how much of the bonus benefit may be reinvested in plan benefits. Compare results at UnitedHealth, CVS Health, Elevance and Centene because ratings can shift market share among insurers. Finally, monitor medical-cost trends: stronger ratings help revenue potential, but profitability still depends on pricing the cost of members’ care accurately.
Core keywords: Humana stock, HUM, Medicare Advantage, CMS Star Ratings, quality bonus payments, Medicare open enrollment, health insurance stocks.
